Victory Capital Management Inc. Purchases 45,161 Shares of RxSight, Inc. (NASDAQ:RXST)

Victory Capital Management Inc. grew its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 21.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 259,864 shares of the company's stock after acquiring an additional 45,161 shares during the quarter. Victory Capital Management Inc. owned about 0.70% of RxSight worth $12,845,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RXST. CWM LLC boosted its position in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company's stock worth $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC grew its position in RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company's stock valued at $29,000 after acquiring an additional 521 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of RxSight during the second quarter valued at approximately $41,000. Amalgamated Bank raised its stake in shares of RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after purchasing an additional 207 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of RxSight during the second quarter worth $156,000. Hedge funds and other institutional investors own 78.78% of the company's stock.

Insider Buying and Selling

In other news, insider Ilya Goldshleger sold 3,100 shares of the company's stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the completion of the sale, the insider now owns 42,246 shares in the company, valued at approximately $2,225,096.82. This represents a 6.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jesse Anderson Corley bought 11,111 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the purchase, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. The trade was a 2.43 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 52,720 shares of company stock valued at $2,603,950 over the last 90 days. 9.36% of the stock is currently owned by company insiders.

RxSight Trading Down 0.7 %

Shares of RXST stock opened at $44.81 on Thursday. RxSight, Inc. has a 1 year low of $27.51 and a 1 year high of $66.54. The stock has a fifty day moving average of $49.78 and a two-hundred day moving average of $52.98.

Analyst Ratings Changes

A number of equities analysts have weighed in on RXST shares. Wells Fargo & Company lowered their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Oppenheimer reduced their price target on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus cut their price objective on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Jefferies Financial Group started coverage on RxSight in a research report on Tuesday, October 29th. They issued a "buy" rating and a $72.00 target price for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight has a consensus rating of "Buy" and a consensus price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.